Abstract: The present invention relates to new 2-amino-5-cyano-4-quinoline-1,4-dihydropyridines, processes for their preparation and their use in medicaments, in particular in agents for the treatment of cardiovascular diseases.

Abstract: The present invention relates to the use of 3-formyl-1,4-dihydropyridine derivatives as medicaments for the control of cardiovascular diseases, in particular of pathologically changed blood pressure and of cardiac insufficiency, new compounds and a process for their preparation.

Abstract: Intermediate compounds of formula IIR.sup.3 --CHO (II)wherein R.sup.3 is ##STR1## and R.sup.6 and R.sup.7 are as defined in the specification, are useful to make compounds having cardiovascular activity.

Abstract: The invention relates to new 4-cinnolinyl- and 4-naphthyridinyl-dihydropyridines of the general formula I ##STR1## in which R.sup.1 to R.sup.5 have the meaning given in the description, to processes for their preparation and intermediates thereof and to their use in medicaments, in particular in compositions having positively inotropic action.

Abstract: The present invention relates to new 2-amino-5-cyano-4-quinoline-1,4-dihydropyridines, processes for their preparation and their use in medicaments, in particular in agents for the treatment of cardiovascular diseases.

Abstract: The invention relates to new 4-cinnolinyl- and 4-naphthyridinyl-dihydropyridines of the general formula I ##STR1## in which R.sup.1 to R.sup.5 have the meaning given in the description, to processes for their preparation and to their use in medicaments, in particular in compositions having positively inotropic action.

Abstract: A process for preparing 3-phenyl-quinoline-5-carboxylic acid comprising reacting 4-amino-3-hydroxyphthalide with phenylacetaldehyde.

Abstract: The invention relates to novel aryl-quinolyl-substituted 1,4-dihydropyridine-di-carboxylic acid derivatives, to processes for their preparation and to their use in drugs, especially for the preparation drugs for the treatment of cardiovascular diseases.

Abstract: 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines which exhibit positive inotropic action with largely neutral vascular behavior, of the formula ##STR1## in which R.sup.1 and R.sup.5 are identical or different and represent straight-chain or branched alkyl having up to 8 carbon atoms,R.sup.2 represents nitro or cyano, orR.sup.1 and R.sup.2 together form a lactone ring of the formula ##STR2## R.sup.3 represents a radical of the formula ##STR3## and R.sup.4 represents hydrogen, orand physiologically acceptable salts thereof.

Abstract: The present invention relates to new 2-amino-5-cyano-4-quinoline-1,4-dihydropyridines, processes for their preparation and their use in medicaments, in particular in agents for the treatment of cardiovascular diseases.

Abstract: The present invention relates to 4-amino-3-hydroxy-phthalide, an important intermediate for the synthesis of 3-substituted-5-quinoline-carboxylic acids and to a process for its preparation.

Abstract: Positive inotropically active 4-quinolyl-dihydropyridines of the formula ##STR1## in which R.sup.1 and R.sup.5 are identical or different and represent straight-chain or branched alkyl having up to 8 carbon atoms,R.sup.2 represents nitro or cyano, orR.sup.1 and R.sup.2 together form a lactone ring of the formula ##STR2## R.sup.3 represents a radical of the formula ##STR3## in which R.sup.6 -denotes hydrogen, halogen or straight-chain or branched alkyl or alkoxy in each case having up to 8 carbon atoms,R.sup.7 denotes aryl, thienyl or pyridyl, andR.sup.4 represents hydrogen, or optionally substituted alkyl, alkenyl, alkadienyl or alkynyl,and their physiologically acceptable salts.

Abstract: 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines which exhibit positive inotropic action with largely neutral vascular behavior, of the formula ##STR1## in which R.sup.1 and R.sup.5 are identical or different and represent straight-chain or branched alkyl having up to 8 carbon atoms,R.sup.2 represents nitro or cyano, orR.sup.1 and R.sup.2 together form a lactone ring of the formula ##STR2## R.sup.3 represents a radical of the formula ##STR3## R.sup.4 -R.sup.7 are defined hereinafter and physiologically acceptable salts thereof.

Abstract: Cardioactive dihydropyridines of the formula ##STR1## in which Y is ##STR2## A is H or CH.sub.3, B is --NH, --NH--CO--, --NH--CS--, --NH--COO--, --NH--SO.sub.2 --or --NH--CO--NH-- or --NH--CS--NH--, andR.sup.13 and R.sup.14 each independently is H or an organic radical,and salts thereof. The Y can be hydrolyzed off. The other radicals on the dihydropyridine moiety can also be varied.

Abstract: Positive inotropically active 4-quinolyl-dihydropyridines of the formula ##STR1## in which R.sup.1 and R.sup.5 are identical or different and represent straight-chain or branched alkyl having up to 8 carbon atoms,R.sup.2 represents nitro or cyano, orR.sup.1 and R.sup.2 together form a lactone ring of the formula ##STR2## R.sup.3 represents a radical of the formula ##STR3## in which R.sup.6 - denotes hydrogen, halogen or straight-chain or branched alkyl or alkoxy in each case having up to 8 carbon atoms,R.sup.7 denotes aryl, thienyl or pyridyl, andR.sup.4 represents hydrogen, or optionally substituted alkyl, alkenyl, alkadienyl or alkynyl,and their physiologically acceptable salts.

Abstract: A method for treating a viral infection in a human or animal patient comprising administering to such patient an antivirally effective amount of a substituted hydroxypiperidine, namely a 2-hydroxymethylene-3,4,5-trihydroxypiperidine.

Abstract: Hypertension and cardiac insufficiency can be controlled by 4-nitrophenyl-dihydropyridine amides of the formula ##STR1## in which X can be ethylene or the like,Y is pyridyl or --NR.sup.9 R.sup.10, andR.sup.9 and R.sup.10 each independently is hydrogenor an organic group, or together form a ring, and physiologically tolerated salts thereof. Compounds in which R.sup.5 and R.sup.6 are not aryl or aralkyl are new.

Abstract: Cardioactive dihydropyridines of the formula ##STR1## in which Y is ##STR2## A is H or CH.sub.3, B is --NH, --NH--CO--, --NH--CS--, --NH--COO--, --NH--SO.sub.2 --or --NH--CO--NH-- or --NH--CS--NH--, andR.sup.13 and R.sup.14 each independently is H or an organic radical,and salts thereof. The Y can be hydrolyzed off. The other radicals on the dihydropyridine moiety can also be varied.

Abstract: Circulation active dihydropyridine amides of the formula ##STR1## in which R.sup.6 represents a group of the formula --O--(CH.sub.2).sub.n --R.sup.10, --S--(CH.sub.2).sub.n --R.sup.10 --O--SO.sub.2 --(CH.sub.2).sub.n R.sup.10 or --O--CO--(CH.sub.2).sub.n --R.sup.10in whichn denotes 0 to 4,andR.sup.10 denotes cyclohexyl, aryl or a heterocyclic ring,and physiologically acceptable salts thereof.

Abstract: Circulation-active fluoromethoxyphenyldihydropyridines of the formula ##STR1## in which X stands for hydrogen or fluorine andR stands for straight-chain, branched or cyclic alkyl or alkenyl having 2 to 12 carbon atoms which can be interrupted by 1 to 2 oxygen and/or sulphur atoms in the chain, and which can be monosubstituted or polysubstituted(a) by hydroxyl, aryl having 6 to 12 carbon atoms, aryloxy having 6 to 12 carbon atoms, where the aryl radical is again substituted by alkyl having up to 4 carbon atoms, alkoxy having up to 4 carbon atoms or halogen, the substituents being identical or different, or(b) by carboxyl, alkoxycarbonyl having up to 6 carbon atoms, pyridyl, piperidyl, pyrimidyl, acyloxy having up to 7 carbon atoms, sulphamoyl, carbamoyl, halogen or cyano, the substituents being identical or different, or(c) by an amino group, where the amino group can carry one or two identical or different substituents from the group consisting of alkyl having up to 6 carbon atoms, benzyl, phenyl or acyl havi